Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. Loibl S, Park YH, Shao Z, Huang CS, et al. N Engl J Med 2025 Dec 10. doi: 10.1056/NEJMoa2514661.

Read + Share

Amedeo Smart

Independent Medical Education

Loibl S, Park YH, Shao Z, Huang CS, et al. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. N Engl J Med 2025 Dec 10. doi: 10.1056/NEJMoa2514661.
PMID: 41370739